Short report: Ramipril and hydrochlorothiazide combination therapy in hypertension: A clinical trial of factorial design

Journal of Hypertension

Volumn 11, Issue 2, 1993, Pages 217-221

  Breitstadt, Axel ^a   Cairns, Victoria ^a   Bauer, Brigitte ^a   Bender, Norbert ^a   Priestley, Christopher ^a   Moreadith, Connie ^b   Phillips, James ^c   Vander Elst, Eric ^c   Koch, Gary ^d  

^a SANOFI   (France)

^b Texalon ^*  (United States)

^c IQVIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Combination therapy; Factorial design; Hydrochlorothiazide; Hypertension; Ramipril

Indexed keywords

HYDROCHLOROTHIAZIDE; PLACEBO; RAMIPRIL;

ADULT; ARTICLE; ASTHENIA; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; VERTIGO;

COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGE; RAMIPRIL; RESEARCH DESIGN; SUPPORT, NON-U.S. GOV'T;

EID: 0027256707     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/00004872-199302000-00015     Document Type: Article

References (12)

1. Gomez HJ, Walker JF, Moncloa F, Orillo VJ, Sromovsky JA, Gabriel M: Enalapril attenuates hydrochlorothiazide-induced hypokalemia, hyperglycemia, hyperuricemia and hypercholesterolemia. In Diuretics. Edited by Puschett JB. Amsterdam: Elsevier; 1984:263–265.
2. Weinberger MH: Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects. J Cardiovasc Pharmacol 1989, 13 (suppl 3):S1–S4.
3. Brunner HR, Gavras H, Waeber B: Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade. Clin Exp Hypertens 1980, 2:639–657.
4. Weinberger MH: Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985, 7 (suppl 1):S52–S55.
5. Todd PA, Benfield P: Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990, 39:110–135.
6. Vasmant D, Bender N: The renin-angiotensin system and ramipril, a new converting enzyme inhibitor. J Cardiovasc Pharmacol 1989, 14 (suppl 4):S46–S52.
7. Hung HMJ, Ng T-H, Chi GYH, Lipicky RJ: Response surface and factorial designs for combination antihypertensive drugs. Drug Info J 1990, 24:371–378.
8. Goldberg MR, Rockhold FW, Offen WW, Dornseif BE: Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther 1989, 46:208–218.
9. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH: An assessment of diltiazem and hydrochlorothiazide in hypertension: application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA 1990, 263:1507–1512.
10. Anonymous: ABC of Hypertension, 1st edn. London: British Medical Association; 1981:1–10.
11. Laska EM, Meisner MJ: Testing whether an identified treatment is best. Biometrics 1989, 45:1139–1151.
12. Phillips JA, Cairns V, Koch GG: The analysis of a multiple dose combination drug clinical trial using response surface methodology. J Biopharmaceut Statist 1992, 2:49–67.